The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

Table 1 Neuropsychological testsin PD patients and control subjects

From: Role of multimodal advanced biomarkers as potential predictors of cognitive and psychiatric aspects of Parkinson's disease

Type of the studied test	Groups		T Test
	Patients	Controls	t	p value
MoCA
Range	21–29	26–30	− 9.467	< 0.001*
Mean ± SD	24.897 ± 2.117	28.156 ± 1.043	− 9.467	< 0.001*
CDRS
Range	0–1	0–0.5	6.460	< 0.001*
Mean ± SD	0.371 ± 0.332	0.033 ± 0.126	6.460	< 0.001*
PD–CRS
Range	69–120	87–130	− 11.166	< 0.001*
Mean ± SD	83.155 ± 12.881	112.511 ± 13.677	− 11.166	< 0.001*
SCOPA–COG-Version2
Range	18–38	29–41	− 15.523	< 0.001*
Mean ± SD	24.724 ± 5.129	37.533 ± 2.351	− 15.523	< 0.001*
HDRS
Range	2–10	0–7	7.542	< 0.001*
Mean ± SD	6.379 ± 2.398	3.200 ± 1.700	7.542	< 0.001*
BDI-II
Range	4–14	0–7	9.732	< 0.001*
Mean ± SD	9.224 ± 2.944	4.378 ± 1.787	9.732	< 0.001*

SD standard deviation, MOCA Montreal Cognitive Assessment, CDRS Clinical Dementia Rating Scale, PD–CRS Parkinson’s Disease–Cognitive Rating Scale, HDRS Hamilton Depression Rating Scale, BDI-II Beck Depression Inventory II
*Significant at p < 0.05

Back to article page